Zyrotram Side Effects

Rapid intravenous administration may be associated with a higher incidence of adverse effects and therefore should be avoided.
The most commonly reported adverse drug reactions are nausea and dizziness, both occurring in more than 10% of patients.
Cardiovascular disorders: Uncommon: cardiovascular regulation (palpitation, tachycardia). These adverse reactions may occur especially on intravenous administration and in patients who are physically stressed. Rare: bradycardia.
Investigations: Rare: increase in blood pressure.
Vascular disorders: Uncommon: cardiovascular regulation (postural hypotension or cardiovascular collapse). These adverse reactions may occur especially on intravenous administration and in patients who are physically stressed.
Metabolism and nutrition disorders: Rare: changes in appetite. Not known: hypoglycaemia.
Respiratory, thoracic and mediastinal disorders: Rare: respiratory depression, dyspnoea.
If the recommended doses are considerably exceeded and other centrally depressant substances are administered concomitantly, respiratory depression may occur.
Worsening of asthma has been reported, though a causal relationship has not been established.
Nervous system disorders: Very common: dizziness. Common: headache, somnolence. Rare: changes in appetite, paraesthesia, tremor, respiratory depression, epileptiform convulsions, involuntary muscle contractions, abnormal coordination, syncope. Not known: speech disorders.
Convulsions occurred mainly after administration of high doses of tramadol or after concomitant treatment with medicinal products which can lower the seizure threshold.
Psychiatric disorders: Rare: hallucinations, confusion, sleep disturbance, delirium, anxiety and nightmares. Psychological adverse reactions may occur following administration of Tramadol hydrochloride injection which vary individually in intensity and nature (depending on personality and duration of treatment). These include changes in mood (usually elation, occasionally dysphoria), changes in activity (usually suppression, occasionally increase) and changes in cognitive and sensorial capacity (e.g. decision behaviour, perception disorders). Dependence may occur.
Symptoms of withdrawal reactions, similar to those occurring during opiate withdrawal, may occur as follows: agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor and gastrointestinal symptoms. Other symptoms that have very rarely been seen with tramadol discontinuation include: panic attacks, severe anxiety, hallucinations, paraesthesias, tinnitus and unusual CNS symptoms (i.e. confusion, delusions, depersonalisation, derealisation, paranoia).
Eye disorders: rare: miosis, mydriasis, blurred vision.
Gastrointestinal disorders: Very common: nausea. Common: vomiting, constipation, dry mouth. Uncommon: retching; gastrointestinal irritation (a feeling of pressure in the stomach, bloating), diarrhoea.
Skin and subcutaneous tissue disorders: Common: sweating. Uncommon: dermal reactions (e.g. pruritus, rash, urticaria).
Musculoskeletal and connective tissue disorders: Rare: motorial weakness.
Hepatobiliary disorders: In a few isolated cases an increase in liver enzyme values has been reported in a temporal connection with the therapeutic use of tramadol.
Renal and urinary disorders: Rare: micturition disorders (difficulty in passing urine, dysuria and urinary retention).
Immune system disorders: Rare: allergic reactions (e.g. dyspnoea, bronchospasm, wheezing, angioneurotic oedema) and anaphylaxis.
General disorders: Common: fatigue.